These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 10870986

  • 1. The stereoselective distribution of halofantrine enantiomers within human, dog, and rat plasma lipoproteins.
    Brocks DR, Ramaswamy M, MacInnes AI, Wasan KM.
    Pharm Res; 2000 Apr; 17(4):427-31. PubMed ID: 10870986
    [Abstract] [Full Text] [Related]

  • 2. Differences in the lipoprotein distribution of halofantrine are regulated by lipoprotein apolar lipid and protein concentration and lipid transfer protein I activity: in vitro studies in normolipidemic and dyslipidemic human plasmas.
    Wasan KM, Ramaswamy M, McIntosh MP, Porter CJ, Charman WN.
    J Pharm Sci; 1999 Feb; 88(2):185-90. PubMed ID: 9950636
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics of halofantrine in the rat: stereoselectivity and interspecies comparisons.
    Brocks DR, Toni JW.
    Biopharm Drug Dispos; 1999 Apr; 20(3):165-9. PubMed ID: 10211870
    [Abstract] [Full Text] [Related]

  • 4. The effect of experimental hyperlipidemia on the stereoselective tissue distribution, lipoprotein association and microsomal metabolism of (+/-)-halofantrine.
    Patel JP, Fleischer JG, Wasan KM, Brocks DR.
    J Pharm Sci; 2009 Jul; 98(7):2516-28. PubMed ID: 18972574
    [Abstract] [Full Text] [Related]

  • 5. The influence of lipids on stereoselective pharmacokinetics of halofantrine: Important implications in food-effect studies involving drugs that bind to lipoproteins.
    Brocks DR, Wasan KM.
    J Pharm Sci; 2002 Aug; 91(8):1817-26. PubMed ID: 12115809
    [Abstract] [Full Text] [Related]

  • 6. Differences in the lipoprotein binding profile of halofantrine in fed and fasted human or beagle plasma are dictated by the respective masses of core apolar lipoprotein lipid.
    McIntosh MP, Porter CJ, Wasan KM, Ramaswamy M, Charman WN.
    J Pharm Sci; 1999 Mar; 88(3):378-84. PubMed ID: 10052998
    [Abstract] [Full Text] [Related]

  • 7. Stereoselective halofantrine and desbutylhalofantrine disposition in the rat: cardiac and plasma concentrations and plasma protein binding.
    Brocks DR.
    Biopharm Drug Dispos; 2002 Jan; 23(1):9-15. PubMed ID: 11891669
    [Abstract] [Full Text] [Related]

  • 8. Influence of physicochemical properties on the patterns of association of a series of aliphatic esters of halofantrine with plasma lipoproteins.
    McIntosh MP, Charman WN, Campbell M, Porter CJ.
    J Control Release; 2004 Mar 05; 95(2):275-89. PubMed ID: 14980776
    [Abstract] [Full Text] [Related]

  • 9. A liquid chromatographic assay for the stereospecific quantitative analysis of halofantrine in human plasma.
    Brocks DR, Dennis MJ, Schaefer WH.
    J Pharm Biomed Anal; 1995 Jun 05; 13(7):911-8. PubMed ID: 8562616
    [Abstract] [Full Text] [Related]

  • 10. Stereoselective pharmacokinetics of desbutylhalofantrine, a metabolite of halofantrine, in the rat after administration of the racemic metabolite or parent drug.
    Brocks DR.
    Biopharm Drug Dispos; 2000 Dec 05; 21(9):365-71. PubMed ID: 11523065
    [Abstract] [Full Text] [Related]

  • 11. Species differences in the proportion of plasma lipoprotein lipid carried by high-density lipoproteins influence the distribution of free and liposomal nystatin in human, dog, and rat plasma.
    Ramaswamy M, Wallace TL, Cossum PA, Wasan KM.
    Antimicrob Agents Chemother; 1999 Jun 05; 43(6):1424-8. PubMed ID: 10348764
    [Abstract] [Full Text] [Related]

  • 12. Direct determination of the enantiomers of the antimalarial drug halofantrine and its active metabolite N-desbutylhalofantrine in human plasma.
    Terefe H, Blaschke G.
    J Chromatogr B Biomed Appl; 1994 Jul 01; 657(1):238-42. PubMed ID: 7952076
    [Abstract] [Full Text] [Related]

  • 13. Association of halofantrine with postprandially derived plasma lipoproteins decreases its clearance relative to administration in the fasted state.
    Humberstone AJ, Porter CJ, Edwards GA, Charman WN.
    J Pharm Sci; 1998 Aug 01; 87(8):936-42. PubMed ID: 9687337
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of the impact of altered lipoprotein binding conditions on halofantrine induced QTc interval prolongation in an anaesthetized rabbit model.
    McIntosh MP, Batey AJ, Coker SJ, Porter CJ, Charman WN.
    J Pharm Pharmacol; 2004 Jan 01; 56(1):69-77. PubMed ID: 14980003
    [Abstract] [Full Text] [Related]

  • 15. Differences in lipoprotein lipid concentration and composition modify the plasma distribution of cyclosporine.
    Wasan KM, Pritchard PH, Ramaswamy M, Wong W, Donnachie EM, Brunner LJ.
    Pharm Res; 1997 Nov 01; 14(11):1613-20. PubMed ID: 9434283
    [Abstract] [Full Text] [Related]

  • 16. Plasma concentrations of the enantiomers of halofantrine and its main metabolite in malaria patients.
    Gimenez F, Gillotin C, Basco LK, Bouchaud O, Aubry AF, Wainer IW, Le Bras J, Farinotti R.
    Eur J Clin Pharmacol; 1994 Nov 01; 46(6):561-2. PubMed ID: 7995326
    [Abstract] [Full Text] [Related]

  • 17. Effect of serum lipoproteins on stereoselective halofantrine metabolism by rat hepatocytes.
    Patel JP, Hamdy DA, El-Kadi AO, Brocks DR.
    Chirality; 2012 Jul 01; 24(7):558-65. PubMed ID: 22589120
    [Abstract] [Full Text] [Related]

  • 18. Effect of altered serum lipid concentrations on the IC50 of halofantrine against Plasmodium falciparum.
    Humberstone AJ, Cowman AF, Horton J, Charman WN.
    J Pharm Sci; 1998 Feb 01; 87(2):256-8. PubMed ID: 9519163
    [Abstract] [Full Text] [Related]

  • 19. Direct determination of the enantiomers of halofantrine and its pharmacologically active metabolite N-desbutylhalofantrine by high-performance liquid chromatography.
    Terefe H, Blaschke G.
    J Chromatogr; 1993 Jun 02; 615(2):347-51. PubMed ID: 8335715
    [Abstract] [Full Text] [Related]

  • 20. The in vitro distribution of halofantrine in human blood and Plasmodium falciparum-parasitised red blood cells.
    Cenni B, Betschart B.
    Chemotherapy; 1995 Jun 02; 41(3):153-8. PubMed ID: 7656659
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.